Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/the-effect-of-raas-blockade-on-the-progression-of-diabetic-nephropathy-GCz40yqGG4
References (116)
-
A. Bomback, P. Klemmer (2007)
The incidence and implications of aldosterone breakthroughNature Clinical Practice Nephrology, 3
-
A. Levin, P. Stevens, R. Bilous, J. Coresh, A. deFrancisco, P. deJong, K. Griffith, B. Hemmelgarn, K. Iseki, E. Lamb, A. Levey, Mc. Riella, M. Shlipak, Hongya Wang, C. White, C. Winearls (2012)
NoticeKidney International Supplements, 3
-
K. Hilgers, R. Veelken (2005)
Type 2 diabetic nephropathy: never too early to treat?Journal of the American Society of Nephrology : JASN, 16 3
-
S. Kagami, W. Border, Diane Miller, N. Noble (1994)
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.The Journal of clinical investigation, 93 6
-
K. Schjoedt, S. Andersen, P. Rossing, L. Tarnow, H. Parving (2004)
Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rateDiabetologia, 47
-
D. Kelly, Yuan Zhang, G. Moe, G. Naik, R. Gilbert, R. Gilbert (2007)
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in ratsDiabetologia, 50
-
P. Sever (2013)
Hypotension and ischaemic stroke associated with aliskiren in the ALTITUDE trial: Sensitisation of the Bezold–Jarisch reflex?Journal of the Renin-Angiotensin-Aldosterone System, 14
-
F. Waanders, Laura Vries, H. Goor, J. Hillebrands, G. Laverman, S. Bakker, G. Navis (2011)
Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.Current vascular pharmacology, 9 5
-
S. Atlas (2007)
The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic InhibitionJournal of Managed Care Pharmacy : JMCP, 13
-
S. Roscioni, D. Zeeuw, S. Bakker, H. Heerspink (2012)
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapyNature Reviews Nephrology, 8
-
M. Slagman, S. Sinkeler, M. Hemmelder, F. Waanders, L. Vogt, H. Kluin-Nelemans, G. Navis, G. Laverman (2010)
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25 10
-
M. Epstein, G. Williams, M. Weinberger, A. Lewin, S. Krause, R. Mukherjee, R. Patni, B. Beckerman (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.Clinical journal of the American Society of Nephrology : CJASN, 1 5
-
M. Mauer, B. Zinman, R. Gardiner, S. Suissa, A. Sinaiko, T. Strand, K. Drummond, S. Donnelly, P. Goodyer, M. Gubler, R. Klein (2009)
Renal and retinal effects of enalapril and losartan in type 1 diabetes.The New England journal of medicine, 361 1
-
F. Persson, P. Rossing, H. Reinhard, T. Juhl, C. Stehouwer, C. Schalkwijk, A. Danser, F. Boomsma, E. Frandsen, H. Parving (2009)
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 32
-
H. Parving, B. Brenner, J. McMurray, D. Zeeuw, S. Haffner, S. Solomon, N. Chaturvedi, F. Persson, Akshay Desai, M. Nicolaides, A. Richard, Zhihua Xiang, P. Brunel, M. Pfeffer (2012)
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.The New England journal of medicine, 367 23
-
Kimberly Gilbert, N. Brown (2010)
Aldosterone and inflammationCurrent Opinion in Endocrinology, Diabetes and Obesity, 17
-
G. Crescenzi, G. Landoni, G. Biondi-Zoccai, F. Pappalardo, M. Nuzzi, E. Bignami, O. Fochi, G. Maj, M. Ranucci, A. Zangrillo (2008)
A Meta-analysis of Randomized Clinical Trials -
M. Ye, J. Wysocki, Josette William, M. Soler, Ivan Cokic, D. Batlle (2006)
Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.Journal of the American Society of Nephrology : JASN, 17 11
-
H. Haller, S. Ito, J. Izzo, A. Januszewicz, S. Katayamá, J. Menne, A. Mimran, T. Rabelink, E. Ritz, L. Ruilope, L. Rump, G. Viberti (2011)
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.The New England journal of medicine, 364 10
-
E. Imai, J. Chan, S. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino, F. investigators (2011)
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled studyDiabetologia, 54
-
Y. Miao, Stefan Ottenbros, G. Laverman, B. Brenner, M. Cooper, H. Parving, D. Grobbee, S. Shahinfar, D. Zeeuw, H. Heerspink (2011)
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan TrialHypertension, 58
-
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
-
F. Hou, D. Xie, Xun Zhang, Ping-yan Chen, Wei Zhang, M. Liang, Zhi-jian Guo, Jian-ping Jiang (2007)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.Journal of the American Society of Nephrology : JASN, 18 6
-
P. Ruggenenti, P. Cravedi, G. Remuzzi (2010)
The RAAS in the pathogenesis and treatment of diabetic nephropathyNature Reviews Nephrology, 6
-
M. Bader (2012)
ACE2, angiotensin-(1–7), and Mas: the other side of the coinPflügers Archiv - European Journal of Physiology, 465
-
M. Onuigbo, N. Onuigbo (2008)
Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.QJM : monthly journal of the Association of Physicians, 101 7
-
M. Slagman, F. Waanders, M. Hemmelder, A. Woittiez, W. Janssen, H. Heerspink, G. Navis, G. Laverman (2011)
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trialThe BMJ, 343
-
D. Zeeuw, G. Remuzzi, H. Parving, W. Keane, Zhongxin Zhang, S. Shahinfar, S. Snapinn, M. Cooper, W. Mitch, B. Brenner (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.Kidney international, 65 6
-
L. Amar, M. Azizi, J. Ménard, S. Peyrard, C. Watson, P. Plouin (2010)
Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary AldosteronismHypertension, 56
-
H. Parving, F. Persson, J. Lewis, E. Lewis, N. Hollenberg (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy.The New England journal of medicine, 358 23
-
M. Tuck, Farida Bounoua, Pirooz Eslami, M. Nyby, P. Eggena, D. Corry (2004)
Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cellsJournal of Hypertension, 22
-
W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, Elizabeth Walker, David Nathan (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.The New England journal of medicine, 346 6
-
S. Grundy, I. Benjamin, G. Burke, A. Chait, R. Eckel, B. Howard, W. Mitch, S. Smith, J. Sowers (1999)
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.Circulation, 100 10
-
Anushka Patel (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 370
-
P. Paassen, D. Zeeuw, G. Navis, P. Jong (2000)
Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 15 5
-
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
-
J. Bosch, S. Yusuf, H. Gerstein, J. Pogue, P. Sheridan, G. Dagenais, R. Diaz, Á. Avezum, F. Lanas, J. Probstfield, G. Fodor, R. Holman (2006)
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, 355 15
-
K. Rossing, K. Schjoedt, B. Jensen, F. Boomsma, H. Parving (2005)
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.Kidney international, 68 3
-
H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.The New England journal of medicine, 345 12
-
A. Barnett, S. Bain, P. Bouter, B. Karlberg, S. Madsbad, J. Jervell, J. Mustonen (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.The New England journal of medicine, 351 19
-
M. Onuigbo (2008)
Radiographic Contrast-Induced Nephropathy and Patient Mortality–2Mayo Clinic Proceedings, 83
-
A. Collins, R. Foley, C. Herzog, B. Chavers, D. Gilbertson, A. Ishani, K. Johansen, B. Kasiske, N. Kutner, Jiannong Liu, W. Peter, Shu Ding, Haifeng Guo, Allyson Kats, K. Lamb, Shuling Li, Suying Li, Tricia Roberts, M. Skeans, J. Snyder, C. Solid, B. Thompson, E. Weinhandl, H. Xiong, A. Yusuf, D. Zaun, Cheryl Arko, Shu‐Cheng Chen, F. Daniels, J. Ebben, Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, B. Forrest, E. Constantini, S. Everson, P. Eggers, L. Agodoa (2013)
US Renal Data System 2012 Annual Data Report.American journal of kidney diseases : the official journal of the National Kidney Foundation, 61 1 Suppl 1
-
H. Heerspink, M. Borst, S. Bakker, G. Navis (2013)
Improving the efficacy of RAAS blockade in patients with chronic kidney diseaseNature Reviews Nephrology, 9
-
J. Josipović, Dajana Katičić, D. Pavlović (2013)
Diabetic nephropathy: diagnosis, prevention and treatment, 19
-
F. Persson, P. Rossing, K. Schjoedt, T. Juhl, L. Tarnow, C. Stehouwer, C. Schalkwijk, F. Boomsma, E. Frandsen, H. Parving (2008)
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.Kidney international, 73 12
-
B. Pitt, L. Køber, P. Ponikowski, M. Gheorghiade, G. Filippatos, H. Krum, C. Nowack, P. Kolkhof, So-Young Kim, F. Zannad (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialEuropean Heart Journal, 34
-
G. Nguyen, D. Muller (2010)
The biology of the (pro)renin receptor.Journal of the American Society of Nephrology : JASN, 21 1
-
M. Gasparo, K. Catt, T. Inagami, J. Wright, T. Unger (2000)
International union of pharmacology. XXIII. The angiotensin II receptors.Pharmacological reviews, 52 3
-
S. Björck, H. Mulec, S. Johnsen, G. Nordén, M. Aurell (1992)
Renal protective effect of enalapril in diabetic nephropathy.British Medical Journal, 304
-
M. Ruíz-Ortega, M. Rupérez, V. Esteban, J. Rodríguez-Vita, E. Sanchez-Lopez, G. Carvajal, J. Egido (2006)
Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 21 1
-
S. Bianchi, Roberto Bigazzi, V. Campese (2005)
Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.American journal of kidney diseases : the official journal of the National Kidney Foundation, 46 1
-
R. Ardaillou (1999)
Angiotensin II receptors.Journal of the American Society of Nephrology : JASN, 10 Suppl 11
-
B. Pitt, S. Anker, D. Bushinsky, D. Kitzman, F. Zannad, I-zu Huang (2011)
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 32
-
P. Ruggenenti, G. Remuzzi (2009)
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature Reviews Nephrology, 5
-
G. Giacchetti, L. Sechi, S. Rilli, R. Carey (2005)
The renin–angiotensin–aldosterone system, glucose metabolism and diabetesTrends in Endocrinology & Metabolism, 16
-
J. Mann, R. Schmieder, M. McQueen, L. Dyal, H. Schumacher, J. Pogue, Xingyu Wang, A. Maggioni, A. Budaj, S. Chaithiraphan, K. Dickstein, M. Keltai, K. Metsärinne, A. Oto, A. Parkhomenko, L. Piegas, T. Svendsen, K. Teo, S. Yusuf (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialThe Lancet, 372
-
F. Nielsen, P. Rossing, M. Gall, P. Skøtt, U. Smidt, H. Parving (1997)
Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic NephropathyDiabetes, 46
-
L. Vogt, F. Waanders, F. Boomsma, D. Zeeuw, G. Navis (2008)
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.Journal of the American Society of Nephrology : JASN, 19 5
-
A. Adler, R. Stevens, S. Manley, R. Bilous, C. Cull, R. Holman (2003)
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).Kidney international, 63 1
-
H. Siragy, R. Carey (2010)
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney DiseaseAmerican Journal of Nephrology, 31
-
B. Perkins, Linda Ficociello, B. Roshan, J. Warram, A. Krolewski (2010)
In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria.Kidney international, 77 1
-
M. Onuigbo (2010)
Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRDRenal Failure, 32
-
A. Mohanram, Zhonxin Zhang, S. Shahinfar, P. Lyle, R. Toto (2008)
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.Kidney international, 73 5
-
M. Bassett, P. White, W. Rainey (2004)
The regulation of aldosterone synthase expressionMolecular and Cellular Endocrinology, 217
-
Uzma Mehdi, B. Adams-Huet, P. Raskin, G. Vega, R. Toto (2009)
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.Journal of the American Society of Nephrology : JASN, 20 12
-
W. Lea, Eun Kwak, J. Luther, Susan Fowler, Zuofei Wang, Ji Ma, A. Fogo, N. Brown (2009)
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.Kidney international, 75 9
-
M. Ravid, D. Brosh, Z. Levi, Y. Bar-Dayan, D. Ravid, R. Rachmani (1998)
Use of Enalapril To Attenuate Decline in Renal Function in Normotensive, Normoalbuminuric Patients with Type 2 Diabetes MellitusAnnals of Internal Medicine, 128
-
P. Ruggenenti, G. Remuzzi (2013)
Dual RAS blockade—controversy resolvedNature Reviews Nephrology, 9
-
A. Meiracker, R. Baggen, S. Pauli, A. Lindemans, A. Vulto, D. Poldermans, F. Boomsma (2006)
Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal functionJournal of Hypertension, 24
-
Tetsuro Nariai, K. Fujita, M. Mori, S. Katayama, S. Hori, K. Matsui (2011)
SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.Journal of pharmacological sciences, 115 3
-
E. Imai, M. Haneda, T. Yamasaki, F. Kobayashi, Atsushi Harada, S. Ito, J. Chan, H. Makino (2013)
Effects of dual blockade of the renin–angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT–Hypertension)Hypertension Research, 36
-
S. Yusuf, H. Gerstein, B. Hoogwerf, J. Pogue, J. Bosch, B. Wolffenbuttel, B. Zinman (2001)
Ramipril and the development of diabetes.JAMA, 286 15
-
A. Forclaz, M. Maillard, J. Nussberger, H. Brunner, M. Burnier (2003)
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?Hypertension: Journal of the American Heart Association, 41
-
M. Lopes-Virella, R. Carter, G. Gilbert, R. Klein, M. Jaffa, A. Jenkins, T. Lyons, W. Garvey, G. Virella (2008)
Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular ComplicationsDiabetes Care, 31
-
J. Hathaway (2012)
HPV: Diagnosis, Prevention, and TreatmentClinical Obstetrics and Gynecology, 55
-
G. Bakris, Mark Williams, L. Dworkin, W. Elliott, Murray Epstein, R. Toto, K. Tuttle, J. Douglas, Willa Hsueh, J. Sowers (2000)
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, 36 3
-
Y. Lacourciére, A. Bélanger, C. Godin, J. Hallé, S. Ross, N. Wright, Jean Marion (2000)
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.Kidney international, 58 2
-
F. Persson, J. Lewis, E. Lewis, P. Rossing, N. Hollenberg, H. Parving (2011)
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Clinical journal of the American Society of Nephrology : CJASN, 6 5
-
Hussam Abuissa, Philip Jones, S. Marso, J. O’Keefe (2005)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.Journal of the American College of Cardiology, 46 5
-
S. Holmer, C. Hengstenberg, B. Mayer, S. Engel, H. Löwel, G. Riegger, H. Schunkert (2001)
Marked suppression of renin levels by β‐receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from β‐blockadeJournal of Internal Medicine, 249
-
H. Parving, U. Smidt, A. Andersen, P. Svendsen (1983)
EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHYThe Lancet, 321
-
A. Apperloo, D. Zeeuw, P. Jong (1997)
A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function.Kidney international, 51 3
-
Tetsuro Nariai, K. Fujita, M. Mori, S. Katayama, S. Hori, K. Matsui (2012)
SM-368229, a Novel Promising Mineralocorticoid Receptor Antagonist, Shows Antihypertensive Efficacy With Minimal Effect on Serum Potassium Level in RatsJournal of Cardiovascular Pharmacology, 59
-
Z. Su, J. Zimpelmann, Kevin Burns (2006)
Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells.Kidney international, 69 12
-
M. Hellemons, F. Persson, S. Bakker, P. Rossing, H. Parving, D. Zeeuw, H. Heerspink (2011)
Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With MicroalbuminuriaDiabetes Care, 34
-
H. Heerspink, F. Holtkamp, H. Parving, G. Navis, J. Lewis, E. Ritz, P. Graeff, D. Zeeuw (2012)
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.Kidney international, 82 3
-
Y. Kanwar, J. Wada, Lin Sun, P. Xie, E. Wallner, Sheldon Chen, S. Chugh, Farhad Danesh (2008)
Diabetic Nephropathy: Mechanisms of Renal Disease ProgressionExperimental Biology and Medicine, 233
-
W. Eijkelkamp, Zhongxin Zhang, G. Remuzzi, H. Parving, M. Cooper, W. Keane, S. Shahinfar, G. Gleim, M. Weir, B. Brenner, D. Zeeuw (2007)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.Journal of the American Society of Nephrology : JASN, 18 5
-
A. Mark (1983)
The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart.Journal of the American College of Cardiology, 1 1
-
D. Raimondo, A. Tuttolomondo, C. Buttá, S. Miceli, G. Licata, A. Pinto (2012)
Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.Current pharmaceutical design, 18 28
-
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, L. Nolan, E. Truscott, N. Walravens, B. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, F. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhorst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, T. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, J. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Andrew Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ, 317
-
A. Grogono, MaryM. Johnson, M. Jastremski, R. Russell (1982)
EDUCATIONAL GRAFFITI: BETTER USE OF THE LAVATORY WALLThe Lancet, 319
-
H Makino (2007)
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetesDiabetes Care, 30
-
D. Zeeuw, D. Ramjit, Zhonxin Zhang, A. Ribeiro, K. Kurokawa, J. Lash, J. Chan, G. Remuzzi, B. Brenner, S. Shahinfar (2006)
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.Kidney international, 69 9
-
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.The New England journal of medicine, 329 20
-
D. Calhoun, W. White, H. Krum, Weinong Guo, G. Bermann, A. Trapani, M. Lefkowitz, J. Ménard (2011)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 TrialCirculation, 124
-
Murray Epstein (2001)
Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.American journal of kidney diseases : the official journal of the National Kidney Foundation, 37 4
-
R. Kunz, C. Friedrich, M. Wolbers, J. Mann (2008)
Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal DiseaseAnnals of Internal Medicine, 148
-
E. Morales, V. Millet, Jorge Rojas-Rivera, A. Huerta, E. Gutiérrez, E. Gutiérrez‐Solís, J. Egido, M. Praga (2013)
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28 2
-
R. Atkins, E. Briganti, J. Lewis, L. Hunsicker, G. Braden, P. Crespigny, G. Deferrari, P. Drury, F. Locatelli, T. Wiegmann, E. Lewis (2005)
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.American journal of kidney diseases : the official journal of the National Kidney Foundation, 45 2
-
J. McMurray, R. Holman, S. Haffner, M. Bethel, B. Holzhauer, T. Hua, Y. Belenkov, M. Boolell, J. Buse, B. Buckley, A. Chacra, F. Chiang, B. Charbonnel, C. Chow, M. Davies, P. Deedwania, P. Diem, D. Einhorn, V. Fonseca, G. Fulcher, Z. Gaciong, S. Gaztambide, T. Giles, E. Horton, H. İlkova, T. Jenssen, S. Kahn, H. Krum, M. Laakso, Lawrence Leiter, N. Levitt, V. Mareev, F. Martínez, C. Masson, T. Mazzone, E. Meaney, R. Nesto, C. Pan, R. Prager, S. Raptis, G. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, I. Sinay, V. Soška, S. Stender, G. Tamás, G. Tognoni, J. Tuomilehto, A. Villamil, J. Vozár, R. Califf (2010)
Effect of valsartan on the incidence of diabetes and cardiovascular events.The New England journal of medicine, 362 16
-
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The New England Journal of Medicine, 330
-
H. Parving, B. Brenner, J. McMurray, D. Zeeuw, S. Haffner, S. Solomon, N. Chaturvedi, M. Pfeffer (2009)
Dual renin-angiotensin system blockade and kidney disease.Journal of the American College of Cardiology, 54 3
-
D. Bhattacharya, C. Aldus, Garry Barton, Christine Bond, Sathon Boonyaprapa, Ian Charles, R. Fleetcroft, Richard Holland, C. Jerosch-Herold, Charlotte Salter, L. Shepstone, Christine Walton, Steve Watson, David Wright (2016)
Randomised controlled trial -
H. Hansen, Peter Rossing, L. Tarnow, F. Nielsen, B. Jensen, Hans-Henrik Parving (1995)
Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.Kidney international, 47 6
-
B. Schrijvers, A. Vriese, A. Flyvbjerg (2004)
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.Endocrine reviews, 25 6
-
M. Onuigbo (2013)
Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature – preventable causes of AKI and SORO-ESRD – a call for re-engineering of nephrology practice paradigmsRenal Failure, 35
-
Christine Richer-Giudicelli, V. Domergue, Marieli González, E. Messadi, M. Azizi, J. Giudicelli, J. Ménard (2004)
Haemodynamic effects of dual blockade of the renin–angiotensin system in spontaneously hypertensive rats: influence of saltJournal of Hypertension, 22
-
W. Catterall, K. Chandy, D. Clapham, G. Gutman, Franz Hofmann, A. Harmar, D. Abernethy, M. Spedding (2003)
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion ChannelsPharmacological Reviews, 55
-
L. Fried, W. Duckworth, Jane Zhang, T. O'connor, M. Brophy, N. Emanuele, Grant Huang, P. McCullough, P. Palevsky, S. Seliger, S. Warren, P. Peduzzi (2009)
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).Clinical journal of the American Society of Nephrology : CJASN, 4 2
-
Y. Miao, Daniela Dobre, H. Heerspink, Barry Brenner, Mark Cooper, H. Parving, Shahnaz Shahinfar, D. Grobbee, D. Grobbee, D. Zeeuw (2010)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialDiabetologia, 54
-
M Ravid (1998)
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trialAnn. Intern. Med., 128
-
GL Bakris (2000)
Preserving renal function in adults with hypertension and diabetes: a consensus approachAm. J. Kidney Dis., 36
-
ME Hellemons (2011)
Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trialDiabetes Care, 34
-
F. Holtkamp, D. Zeeuw, Merlin Thomas, M. Cooper, P. Graeff, H. Hillege, H. Parving, B. Brenner, S. Shahinfar, H. Heerspink (2011)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.Kidney international, 80 3
-
P. Ruggenenti, A. Fassi, Anelja Ilieva, Simona Bruno, I. Iliev, Varusca Brusegan, N. Rubis, Giulia Gherardi, Federica Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A. Dodesini, G. Remuzzi (2004)
Preventing microalbuminuria in type 2 diabetes.The New England journal of medicine, 351 19
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
- Subject
- Medicine & Public Health; Medicine/Public Health, general; Nephrology
- ISSN
- 1759-5061
- eISSN
- 1759-507X
- DOI
- 10.1038/nrneph.2013.251
- Publisher site
- See Article on Publisher Site
Abstract
Renin–angiotensin–aldosterone system (RAAS) blockade using angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers, which have antihypertensive and antialbuminuric properties, has become the cornerstone of treatment of diabetic renal disease As single-agent RAAS blockade does not completely block RAAS activation the residual renal risk of treated patients is high Data from clinical trials of dual RAAS blockade (including the use of aldosterone blockers or renin inhibitors) are contradictory and safety remains a concern Possible alternatives to dual RAAS blockade include restricting dietary sodium, increasing drug doses or using novel drugs to block the deleterious effects of RAAS activation whilst preserving its physiological role Novel omic techniques might enable the identification of patients who are most likely to benefit from RAAS blockade and the individual tailoring of interventions
Journal
Nature Reviews Nephrology – Springer Journals
Published: Dec 3, 2013